

Katia A Mesquita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2314191/publications.pdf>

Version: 2024-02-01

14
papers

456
citations

933264

10
h-index

1058333

14
g-index

14
all docs

14
docs citations

14
times ranked

1009
citing authors

#	ARTICLE	IF	CITATIONS
1	Injectable laminin-biofunctionalized gellan gum hydrogels loaded with myoblasts for skeletal muscle regeneration. <i>Acta Biomaterialia</i> , 2022, 143, 282-294.	4.1	13
2	Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers. <i>Theranostics</i> , 2021, 11, 8350-8361.	4.6	10
3	FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. <i>Cancers</i> , 2021, 13, 1866.	1.7	12
4	Cell quality control mechanisms maintain stemness and differentiation potential of P19 embryonic carcinoma cells. <i>Autophagy</i> , 2020, 16, 313-333.	4.3	18
5	PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers. <i>Cancer Letters</i> , 2020, 469, 124-133.	3.2	22
6	ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers. <i>Cancers</i> , 2019, 11, 1149.	1.7	9
7	ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers. <i>Gynecologic Oncology</i> , 2019, 153, 416-424.	0.6	26
8	Development and implementation of precision therapies targeting base-excision DNA repair in BRCA1-associated tumors. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 11-25.	0.4	1
9	Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma <i>in Situ</i> Induces Synthetic Lethality and Chemoprevention. <i>Cancer Research</i> , 2018, 78, 6818-6827.	0.4	26
10	Mitochondrial biology in cancer stem cells. <i>Seminars in Cancer Biology</i> , 2017, 47, 18-28.	4.3	42
11	Melatonin antiproliferative effects require active mitochondrial function in embryonal carcinoma cells. <i>Oncotarget</i> , 2015, 6, 17081-17096.	0.8	28
12	Mitochondrial metabolism directs stemness and differentiation in P19 embryonal carcinoma stem cells. <i>Cell Death and Differentiation</i> , 2014, 21, 1560-1574.	5.0	91
13	Mitochondria in Cancer Stem Cells: A Target for Therapy. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2013, 7, 102-114.	0.7	49
14	In Vitro Surfactant Structure-Toxicity Relationships: Implications for Surfactant Use in Sexually Transmitted Infection Prophylaxis and Contraception. <i>PLoS ONE</i> , 2011, 6, e19850.	1.1	109